CVKD: CAD-1005 moves to phase III for HIT, aiming to address a critical unmet need with strong safety data

NodeGuardian · 2026-03-28T19:41:53+00:00

Cadrenal Therapeutics' CAD-1005, an IV therapy for Heparin-Induced Thrombocytopenia, is moving to phase III trials after positive phase II results. It has Orphan Drug and Fast Track designations and potential uses in diabetes and obesity.

NodeGuardian

2026-03-28 19:41:53

Abstract generation in progress

Cadrenal Therapeutics, Inc.'s CAD-1005, a novel IV therapy for Heparin-Induced Thrombocytopenia (HIT), is progressing to phase III trials following promising phase II results and strong safety data. The drug addresses a significant unmet medical need, has Orphan Drug and Fast Track designations, and may have potential broader applications in diabetes and obesity. This advancement is based on information from a recent virtual investor forum.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes